ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Post-Hoc Study Analysis Examines Early Intervention with Edaravone for ALS Survival
March 25, 2021Mitsubishi Tanabe Pharma America announced a post-hoc analysis of its Phase 3 edaravone study reviewing the results of intravenous (IV) edaravone treatment on disease progression milestones and events among people with amyotrophic lateral sclerosis (ALS).
Pharma Sources Insight January 2025
